13.07.2015 Views

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

1. General Introductionhighly v<strong>as</strong>cularized, which makes pulmonary targeting difficult because of f<strong>as</strong>t absorption ofmost <strong>drug</strong>s (especially lipophilic <strong>and</strong> low molecular weight <strong>drug</strong>s).1.4. Pulmonary Drug Delivery Following Aerosol TherapyThere are several advantages in delivering <strong>drug</strong>s, such <strong>as</strong> antimicrobial agents, to the lungsincluding a non inv<strong>as</strong>ive method of <strong>delivery</strong>; a large surface area for absorption (~75m 2 ); thin(0.1 to 0.5 µm) alveolar epithelium, permitting rapid absorption; absence of first-p<strong>as</strong>smetabolism; rapid onset of action; <strong>and</strong> high bioavailability.Since the advent of nebulizer therapy in 1859, nebulizers have been used to treat a range ofpulmonary dise<strong>as</strong>es in pediatric <strong>and</strong> adult populations, including <strong>as</strong>thma, chronic obstructivepulmonary dise<strong>as</strong>e (COPD), <strong>and</strong> cystic fibrosis (CF).The expansion of nebulizer therapy inthe mid to late 20th century for common respiratory dise<strong>as</strong>es h<strong>as</strong> been followed by a focus onuse for more specific indications <strong>and</strong> certain new applications.The development of an inhalant therapy that is efficacious <strong>and</strong> safe depends not only on apharmacologically active molecule, but also on a well-designed <strong>delivery</strong> system <strong>and</strong>formulation. It is the optimization of the whole system (<strong>drug</strong>, <strong>drug</strong> formulation <strong>and</strong> device)that is necessary for the successful development of inhalation therapies, both new <strong>and</strong> old, forthe treatment of local <strong>and</strong> systemic dise<strong>as</strong>es. Drug–device combinations must aerosolize the<strong>drug</strong> in the appropriate particle size distribution <strong>and</strong> concentration to ensure optimaldeposition <strong>and</strong> dose in the desired region of the lung.Although the traditional form of inhalation therapy dates back to the earliest records ofancient cultures, the advantages of inhalation therapy have essentially remained the same.Several studies (1–3) have demonstrated the clinical advantage of inhalation aerosols oversystemic therapy for the treatment of lung disorders. Relatively small doses are required foreffective therapy, reducing systemic exposure to <strong>drug</strong> <strong>and</strong> thus minimizing adverse effects.Delivering small doses of active ingredients directly to the lung effectively targets the <strong>drug</strong>,thereby maximizing therapeutic effect while minimizing adverse effects.1.4.1. Delivery Device: Jet NebulizerNebulizers have been used for many years to treat <strong>as</strong>thma <strong>and</strong> other respiratory dise<strong>as</strong>es.There are two b<strong>as</strong>ic types of nebulizer, jet <strong>and</strong> ultr<strong>as</strong>onic nebulizers. Ultr<strong>as</strong>onic nebulizersutilize high frequencies to convert liquid into a fine mist (74).18

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!